 BENSALEM, Pa.--BUSINESS WIRE--- ORPH CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of Orphazyme AS Orphazyme or the Company NASDAQ: ORPH investors concerning the Companys possible violations of federal securities laws. Orphazyme is a biopharmaceutical company that develops therapies for the treatment of neurodegenerative orphan diseases. Its leading drug candidate is arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease 